ABBV vs AMD: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Advanced Micro Devices, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-16.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Advanced Micro Devices, Inc. · Technology
$278.26
+40.5% upside to fair value
High Conviction
Grade B+
QuantHub Verdict
AMD has more upside to fair value
(+40.5%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
AMD |
| Current Price |
$208.05 |
$278.26 |
| Fair Value Estimate |
$217.50 |
$391.00 |
| Upside to Fair Value |
+4.5%
|
+40.5%
|
| Market Cap |
$367.9B |
$453.7B |
| Forward P/E |
14.9x
|
104.6x
|
| EV / EBITDA |
16.7x
|
—
|
| Price / Sales |
6.1x
|
13.1x
|
| Price / FCF |
20.9x
|
67.4x
|
| Revenue Growth YoY |
+8.6%
|
+11.1%
|
| Gross Margin |
83.7%
|
49.5%
|
| Operating Margin |
34.7%
|
10.7%
|
| Return on Equity |
-129.24%
|
7.2%
|
| Dividend Yield |
3.2% |
— |
| FCF Yield |
4.78%
|
1.5%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
AMD has solidified its position as a premier challenger to NVIDIA in AI GPUs and Intel in CPUs, fueled by explosive Data Center growth reaching $16.6 billion in 2025, up 32% year-over-year, alongside robust Client and Gaming expansion to $14.6 billion, up 51%. Under CEO Lisa Su's leadership, the company achieved 34% total revenue growth to $34.6 billion in 2025 with net income of $4.3 billion, ye…
Accumulation Zones
| Metric |
ABBV |
AMD |
| Zone Low |
$163.13 |
$293.00 |
| Zone High |
$184.88 |
$332.00 |
| In Buy Zone? |
No
|
Yes
|